Prasugrel Versus Double Clopidogrel to Overcome Platelet Reactivity Early Following a 600mg Clopidogrel Loading Dose In Patients Undergoing Primary Percutaneous Coronary Intervention  by unknown
FEATURED CLINICAL RESEARCH
after stenting assessed by Optical frequency domain tomography imaging (OFDI,
TERUMO Corporation, Tokyo, Japan) between the 2 treatment arms. Flow area is
defined as: (Stent area + incomplete stent apposition area) – (intraluminal defect area
attached to the wall + intraluminal defect area free from the wall). The sample size of
60 patients in each group would achieve 80% power to detect a difference of 0.72 mm2
in minimal flow area.
Results: As of July 31, 109 patients were enrolled. 72% of the enrolled patients were
male, 43% had current smoking habit, and 5% had diabetes mellitus. Treated vessels
were RCA in 35%, LCx in 14% and LAD in 41%. 23% of the patients were treated
using radial access. In some cases, OFDI documented a presence of significant amount
of intraluminal mass (Figure). The interim, blinded OFDI analysis of the first 62
patients showed the minimal flow area of 7.08±1.98 mm2 and mean flow area of
8.67±2.17 mm2.
Conclusion: The results of primary endpoint, the complete and unblinded OFDI
analysis of minimal flow area in the two groups will be presented at the meeting.
Prasugrel Versus Double Clopidogrel to Overcome Platelet Reactivity Early
Following a 600mg Clopidogrel Loading Dose In Patients Undergoing Primary
Percutaneous Coronary Intervention.
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Konstantinos Theodoropoulos,
Georgios Kassimis, Ioannis Chiladakis, Periklis Davlouros, George Hahalis
Background: Platelet reactivity (PR) assessment in the very early phase (2 hours post
600mg clopidogrel loading dose-LD) of ST-elevation myocardial infarction (STEMI)
has not been previously reported nor any possible ways to overcome high on-treatment
PR (HTPR).
Methods: In STEMI patients undergoing primary PCI, PR was assessed with the
VerifyNow (Accumetrics Inc., San Diego, CA, USA) assay 2 hours after a 600mg
clopidogrel LD. Patients with HTPR (≥ 235 PR Units), were randomized to either
immediate reloading with 60mg prasugrel/10mg maintenance dose (MD) (group-A)
or clopidogrel 150mg MD starting from the next day (group-B). PR was re-assessed
at 2, 24 hours and at 5 days following randomization. Genotyping was performed for
CYP2C19*2 carriage.
Results: Out of 81 STEMI patients screened, 52(64.2%) demonstrated HTPR 2 hours
post LD and were all randomized (26 group-A and 26 group-B). PR at 2 hours, 24
hours and 5 days post randomization was lower in group- A compared to group-B
(Figure 1). HTPR rates were lower for group-A compared to group-B at 2 and 24 hours
post randomization (44.0% vs 76.9%, p=0.023 and 3.8% vs 61.5%, p<0.001
respectively) and marginally lower at 5 days post randomization (8.0% vs 30.8%,
p=0.075). HTPR rates were affected by CYP2C19*2 carriage mainly in group-B.
Conclusion: In STEMI patients, HTPR 2 hours following 600 mg of clopidogrel LD
is very common. An additional reloading with 60 mg of prasugrel followed by a 10 mg
MD, achieves greater platelet inhibition compared to clopidogrel 150 mg MD as early
as in 2 hours, a difference that is maintained up to 5 days. Complete genotyping
analysis will be presented. Platelet reacticity at 2, 24 hours and 5 days post
randomization.
The Evaluation of the Influence of Statins and Proton Pump Inhibitors on
Clopidogrel Antiplatelet Effect (SPICE) Trial
Jean-Pierre P. Dery, Ugo Déry, Stephane Rinfret, Eric Larose, Josep Rodes-Cabau,
Robert DeLarochellière, Mélanie Roy, Pierre-Louis Nadeau, Rodrigo Bagur, Helena
Tizon-Marcos, Louis Roy, Can M. Nguyen, Gerald Barbeau, Guy Proulx, Onil
Gleeton, Bernard Noel, Olivier F. Bertrand
Background: Previous pharmacodynamic studies have demonstrated that proton pump
inhibitors (PPI) and statins may interfere with the antiplatelet effect of clopidogrel.
Methods: SPICE was a single center prospective randomized open-label with blinded
endpoints trial. The primary objective was to compare the impact of 4 different anti-
acid therapies on the antiplatelet effect of clopidogrel. The secondary objective was to
determine which factors modulate this drug-drug interaction, including the choice of
statin and the presence of 2C19*2 polymorphism. After PCI, 320 patients were
randomized to rosuvastatin 20mg id or atorvastatin 80mg id. At 30 days, patients were
randomized again to either omeprazole 20mg id, pantoprazole 40mg id, esomeprazole
40mg id, or ranitidine 300mg id, stratified by statin group and 2C19*2 carrier state.
Platelet function tests were performed before and after 30 days of constant anti-acid
therapy. The study had 87% power to detect an absolute difference of 10% in the mean
change in maximal platelet aggregation (MPA) between two anti-acid groups in the
stratum of patients carrying the 2C19*2 polymorphism.
Results: As of August 1st, 319 patients have been recruited. Median age was 61 years.
Reason for PCI was ACS for 71% of patients. Thirty-day and 60-day platelet function
tests were available for 274 and 243 patients, respectively. After 30 days of anti-acid
therapy, MPA increased from 38.6% to 39.2% (p=0.8) in the ranitidine group and from
35.1% to 40.5% (p=0.0004) in the PPI groups combined. Similarly, platelet reactivity
index (VASP) increased from 44.9% to 47% (p=0.6) in ranitidine-treated patients and
from 42.8% to 49.6% p<0.0001) in PPI-treated patients. 
Conclusion: In patients receiving clopidogrel after PCI, concomitant anti-acid therapy
with proton-pump inhibitors decreased the antiplatelet effect of clopidogrel while the
H2 receptor blocker ranitidine had no impact on platelet reactivity. The differential
effect of each PPI and the role of the choice of statin and 2C19*2 polymorphism on this
drug-drug interaction will be presented at the meeting.
Vasoreactivity Results of Cohort 1 at Six Month Post Implantation of the Drug
Eluting Absorbable Metal Scaffold in the BIOSOLVE-I Study
Raimund Erbel, Dirk Böse, Michael Haude, Hubertus Degen, Stefan Verheye, Paul
Vermeersch, Paul Erne, Ron Waksman, Jacques Koolen
Background: Absorbable metal scaffolds (AMS) were developed for the treatment of
coronary artery stenosis. The major advantages of AMS after bioabsorption, are that
they only leave behind the natural healed vessel within 6 -12 months post implantation.
Most recently a new drug (Paclitaxel) eluting AMS (DREAMS) was developed to
reduce the revascularization rates. The aim of this substudy was to evaluate the
restoration of vasoreactivity 6 months post implantation.
Methods: BIOSOLVE-I is a prospective, multicenter first in man trial for the
evaluation of DREAMS in the treatment of coronary stenosis with follow-up
investigations at 1, 6, 12, 24 and 36 months. Vasomotion test was performed at a
subgroup of the patients during 6 month follow-up at two study sites. Endothelium
dependent vasoactive agent acetylcholine (ACH) was administered intracoronary in
different doses (0.36 µg/mL, 3.6 µg/ml and 18 µg/mL) in order to evaluate
vasoreactivity during follow-up. Quantitative coronary angiography was done to assess
coronary dimensions during vasomotion testing.
Results: Vasomotion test was performed in 14 patients (11 males/3 females) of cohort
1 with a mean age of 65.6 ± 10.0 years. Hypertension (92.9%), hyperlipidemia (85.7%),
were the major cardiovascular risk factors and history of myocardial infarction was
present in 42.9% of the subjects. Type A (50.0%), Type B1 (42.9%) and Type B2 (7.1%)
lesions were treated with a 3.25 / 16mm (50.0%) or a 3.5 / 16mm (50.0%) DREAMS.
During 6 month follow-up the mean lumen diameter was 2.55 ± 0.8mm in the treated
segment and 2.64 ± 0.96mm and 2.40 ± 0.66mm in the proximal and distal reference
segment. After infusion of ACH, the lumen dimensions decreased to 2.25 ± 0.9mm in
the treated segment and 2.42 ± 0.95mm and 2.08 ± 0.82mm in the reference segments.
Conclusion: Coronary arteries undergoing DREAMS implantation regains vasomotor
function at the treated segment at 6 months as reflected by vasoconstriction of the
scaffold segment. These observations support scaffolding bioabsorption with
restoration of vessel vasoreacitivity.
Comparison of Resolute Zotarolimus-Eluting Stent and Sirolimus-Eluting
Stents in Patients with Long Coronary Artery Lesions: A Randomized LONG-
DES IV Trial
Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Young Lee, Soo-Jin Kang,
Seung-Whan Lee, Cheol-Whan Lee, Seong-Wook Park, Sung Yun Lee, Bong Ki Lee ,
Jang-Hyun Cho, Tae-Hyun Yang, Nae-Hee Lee, Joo-Young Yang, Jong-Seon Park,
Won-Yong Shin, Moo Hyun Kim, Jang Ho Bae, Myeong-Kon Kim, Junghan Yoon,
Seung-jung Park
Background: Outcomes remain relatively unfavorable for stent-based coronary
intervention of lesions with long diseased segments.
Methods: This randomized, multicenter, prospective trial compared the Resolute
zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES) in 500 patients
with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-
segment late luminal loss at 9 months angiographic follow-up.
Results: The ZES and SES groups had similar baseline characteristics. Lesion length
was 32.4±13.5 mm in the ZES group and 31.0±13.5 mm in the SES group (P=0.27).
Nine-month angiographic follow-up was performed in 70% of eligible patients. In-
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